Search

Your search keyword '"Eyal, Nir"' showing total 658 results
Start Over Author "Eyal, Nir" Publication Year Range Last 50 years
658 results on '"Eyal, Nir"'

5. Contributors

Author

Adams, Axel, primary, Affun-Adegbulu, Clara, additional, Al-Rasheed, Rakan S., additional, Alaska, Yasser A., additional, Aldawas, Abdulaziz D., additional, Alesa, Saleh Ali, additional, Alexander, George A., additional, Alhadhira, Abdullah Ahmed, additional, Alhajjaj, Fahad Saleha, additional, Alhazmi, Hazem H., additional, Alhussaini, Zainab Abdullah, additional, Aljerian, Nawfal, additional, Aljohani, Majed, additional, AlKhaldi, Khaldoon H., additional, Alkhattabi, Eyad, additional, Allen, Bryant, additional, Almand, Austin, additional, Alnoaimi, Moza M., additional, Alotaibi, Mohammad, additional, Alpert, Evan Avraham, additional, Alrusayni, Yasir A., additional, Alshammari, Mai, additional, Alsulimani, Loui K., additional, Amanullah, Siraj, additional, Anderson, Arian, additional, Arastehmanesh, David, additional, Ardalan, Ali, additional, Argote-Araméndiz, Killiam A., additional, Artenstein, Andrew W., additional, Bailey, Olivia E., additional, Baker, Russell, additional, Balsari, Satchit, additional, Banner, Gregory T., additional, M, Fermin Barrueto, additional, Bartels, Susan A., additional, Baugh, Joshua J., additional, Berg, Frederic, additional, Bhola, Vijai, additional, Binder, William, additional, Bortolin, Michelangelo, additional, Bounes, Vincent, additional, Bouton, Michael, additional, Brown, Natasha, additional, Jr, Frederick M. Burkle,, additional, Burnett, Lynn Barkley, additional, Burns, Michele M., additional, Sr, Nicholas V. Cagliuso,, additional, Cahill, John, additional, Callaway, David W., additional, Caneva, Duane C., additional, Cattamanchi, Srihari, additional, Caycedo, Alejandra, additional, Cetaruk, Edward W., additional, Chacko, Sneha, additional, Chang, James C., additional, Chiang, Crystal, additional, Chiu, David T., additional, Ciottone, Gregory R., additional, Ciottone, Jonathan Peter, additional, Ciottone, Melissa A., additional, Ciottone, Robert A., additional, Ciottone, Robert G., additional, Ciottone, Vigen G., additional, Clark, Alexander, additional, Clark, Jonathan, additional, Conley, Sean P., additional, Cono, Joanne, additional, Cooper, Arthur, additional, Cormier, Scott B., additional, Court, Michael F., additional, Cunningham, Cord W., additional, Czarnecki, Fabrice, additional, Davis, Supriya, additional, Davis, Timothy E., additional, DeMers, Gerard, additional, Dilling, Sharon, additional, Djalali, Ahmadreza, additional, Donahoe, Timothy, additional, Donahue, Joseph, additional, Dresser, Caleb, additional, Dylik, Jason, additional, Easter, Benjamin, additional, Eastman, Alexander, additional, Ebbeling, Laura, additional, Emetarom, Chigozie, additional, Eyal, Nir, additional, Eyre, Andrew J., additional, Freeman, David J., additional, Friedman, Franklin D., additional, Fritz, Christie, additional, Fung, Frederick, additional, Gallahue, Fiona E., additional, Garbern, Stephanie Chow, additional, Gebhart, Mark E., additional, Gluckman, William A., additional, Goolsby, Craig, additional, Gougelet, Robert M., additional, Granholm, Fredrik, additional, Greenough, P. Gregg, additional, Grimes, Jennifer O., additional, Grosse, Steve, additional, Grossman, Shamai A., additional, Jr, John T. Groves, additional, Guidotti, Tee L., additional, Guo, George, additional, Haessler, Sarah, additional, Hall, Matthew M., additional, Hardin, John W., additional, Harrell, Mason, additional, Hart, MD, Alexander, additional, Harvey, Melissa, additional, Hertelendy, PhD, Attila J., additional, Hiremath, Nishanth S., additional, Hitchens, Jordan, additional, Holstege, Christopher P., additional, Horne, Simon T., additional, Horng, Steven, additional, Hosin, Amer, additional, House, Hans R., additional, Ingrassia, Pier Luigi, additional, Issa, Fadi S., additional, Jacoby, Irving “Jake”, additional, Jaiswal, Rajnish, additional, Jay, Gregory, additional, Jenkins, J. Lee, additional, Joseph, Josh W., additional, Kappler, Shane, additional, Keim, Mark E., additional, Kelman, Julie, additional, Ketterer, Andrew R., additional, Khan, Anas A., additional, Kharel, Ramu, additional, Kharod, Chetan U., additional, Kirsch, Thomas D., additional, Knopov, Anita, additional, Kravitz, Max, additional, Lee, J. Austin, additional, Lemery, Jay, additional, Leventhal, Evan L., additional, Loughlin, Jesse, additional, Ludy, Stephanie, additional, Maguire, Brian J., additional, Mahon, Selwyn E., additional, Maniscalco, Paul M., additional, Manners, Philip, additional, Marcus, Leonard Jay, additional, Margus, Colton, additional, Masri, Taha M., additional, Matthews, Jeff, additional, McKay, Sean D., additional, McKinney, Zeke J., additional, McLellan, Robert K., additional, McNulty, Eric J., additional, Mehkri, Faroukh, additional, Mehta, Mandana, additional, Mendelsohn, Rebecca A., additional, Merin, Ofer, additional, Milsten, Andrew, additional, Molé, Dale M., additional, Molloy, Michael Sean, additional, Morelli, Ilaria, additional, Mothershead, Jerry L., additional, Mulhern, John, additional, Mullendore, Nicole F., additional, Musisca, Nicholas J., additional, Naganathan, Sonya, additional, Nathanson, Larry A., additional, Nelson, Erica L., additional, Nelson, Lewis S., additional, Newbury, Bradford A., additional, Newbury, Kimberly, additional, O’Neill, Ansley, additional, Obernier, Robert, additional, Olagnero, Jacopo M., additional, Oostrom-Shah, Leonie, additional, Ordun, Catherine Y., additional, Parazynski, Scott, additional, Park, Andrew J., additional, Partridge, Robert, additional, S, Jeffrey, additional, Phillips, James P., additional, Pinter, Emily, additional, IV, David P. Polatty, additional, Popieluszko, Patrick, additional, Porcaro, William, additional, Proano, Lawrence, additional, Pruitt, Peter B., additional, Qureshi, Moiz, additional, Ragazzoni, Luca, additional, Rashid, Murtaza, additional, Rega, Paul Patrick, additional, Reilly, Michael J., additional, Restuccia, Marc C., additional, Rifino, James J., additional, Robben, Paul M., additional, Rosenblatt, Joy L., additional, Ryan, Kevin M., additional, Rybasack-Smith, Heather, additional, Salway, Richard James, additional, Samo, Daniel, additional, Sanchez, Leon D., additional, Sanford, Shawn M., additional, Sarin, Ritu R., additional, Sarma, Deesha, additional, Schacht, Jesse, additional, Schwind, Valarie, additional, Shapiro, Geoffrey L., additional, Sheehan, Joshua, additional, Shreve, Brian, additional, Simonyan, Grigor, additional, Smith, Devin M., additional, MD, E. Reed Smith,, additional, MA, Jack E. Smith,, additional, Smith, Montray, additional, Smulowitz, Peter B., additional, Snyder, Angela M., additional, Solano, Joshua J., additional, Stenson, Bryan A., additional, Stewart, Charles, additional, Stewart, M. Kathleen, additional, Sullivan, Patrick, additional, Supple, Jared S., additional, Tin, Derrick, additional, Valente, Jonathan Harris, additional, Vear, Kathryn M., additional, Vidyalakshmi, P.R., additional, Vilas, Faith, additional, Vilke, Gary M., additional, Villano, Janna H., additional, Voskanyan, Amalia, additional, Watson, C. James, additional, Weber, Nancy, additional, Weiner, Scott G., additional, Weinstein, Brielle, additional, Weinstein, Eric S., additional, Werner, Jordan R., additional, MD, Roy Karl Werner,, additional, Whitledge, James D., additional, Wiener, Sage W., additional, Wiesner, Lauren, additional, Williams, Kenneth A., additional, Wing, Robyn, additional, Wolfe, Richard E., additional, Wong, Wendy Hin-Wing, additional, Woolard, Robert, additional, Wuthisuthimethawee, Prasit, additional, and Youssef, Nadine A., additional

Published
2024
Full Text
View/download PDF

6. Broad cross-national public support for accelerated COVID-19 vaccine trial designs

Author

Broockman, David, Kalla, Joshua, Guerrero, Alexander, Budolfson, Mark, Eyal, Nir, Jewell, Nicholas P, Magalhaes, Monica, and Sekhon, Jasjeet S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Vaccine Related, Immunization, Good Health and Well Being, Asia, Australia, COVID-19, COVID-19 Vaccines, Choice Behavior, Clinical Trials as Topic, Decision Making, Female, Humans, Immunity, Innate, Immunization Schedule, Immunogenicity, Vaccine, Male, North America, Pandemics, Patient Safety, Public Health, Research Design, SARS-CoV-2, Surveys and Questionnaires, Time Factors, United Kingdom, Vaccination, Vaccine ethics, Challenge trials, Public opinion, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

A vaccine for COVID-19 is urgently needed. Several vaccine trial designs may significantly accelerate vaccine testing and approval, but also increase risks to human subjects. Concerns about whether the public would see such designs as ethical represent an important roadblock to their implementation; accordingly, both the World Health Organization and numerous scholars have called for consulting the public regarding them. We answered these calls by conducting a cross-national survey (n = 5920) in Australia, Canada, Hong Kong, New Zealand, South Africa, Singapore, the United Kingdom, and the United States. The survey explained key differences between traditional vaccine trials and two accelerated designs: a challenge trial or a trial integrating a Phase II safety and immunogenicity trial into a larger Phase III efficacy trial. Respondents' answers to comprehension questions indicate that they largely understood the key differences and ethical trade-offs between the designs from our descriptions. We asked respondents whether they would prefer scientists to conduct traditional trials or one of these two accelerated designs. We found broad majorities prefer for scientists to conduct challenge trials (75%) and integrated trials (63%) over standard trials. Even as respondents acknowledged the risks, they perceived both accelerated trials as similarly ethical to standard trial designs. This high support is consistent across every geography and demographic subgroup we examined, including vulnerable populations. These findings may help assuage some of the concerns surrounding accelerated designs.

Published
2021

7. “Cure” Versus “Clinical Remission”: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication

Author

Fridman, Ilona, Ubel, Peter A, Blumenthal-Barby, Jennifer, England, Cameron V, Currier, Judith S, Eyal, Nir, Freedberg, Kenneth A, Halpern, Scott D, Kelley, Colleen F, Kuritzkes, Daniel R, Le, Catherine N, Lennox, Jeffrey L, Pollak, Kathryn I, Zikmund-Fisher, Brian J, and Scherr, Karen A

Subjects
Public Health, Health Sciences, Clinical Research, Behavioral and Social Science, Clinical Trials and Supportive Activities, HIV/AIDS, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Decision Making, Drug Therapy, Female, HIV Infections, Humans, Intention, Male, Middle Aged, Patients, Research Personnel, Surveys and Questionnaires, Behavior, Cure, Decision-making, HIV, PLWHIV, Remission, Public Health and Health Services, Social Work, Public health
Abstract

Many people living with HIV (PLWHIV) state that they would be willing to take significant risks to be "cured" of the virus. However, how they interpret the word "cure" in this context is not clear. We used a randomized survey to examine whether PLWHIV had a different willingness to take a hypothetical HIV medication if it causes flu-like symptoms, but provides: (a) cure, (b) remission that was labeled "cure", or (c) remission. PLWHIV (n = 454) were more willing to take a medication that provided a "cure" versus a "remission" if the side effects lasted less than 1 year. PLWHIV were more willing to take a medication that provided a remission that was labeled "cure" versus a "remission" (p = 0.01) if the side effects lasted 2 weeks. Clinicians and researchers should be aware of the impact of the word "cure" and ensure that PLWHIV fully understand the possible outcomes of their treatment options.

Published
2020

10. Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium

Author

Eyal, Nir and Deeks, Steven G

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Sexually Transmitted Infections, HIV/AIDS, Infectious Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Adult, Aged, Aged, 80 and over, Anti-Retroviral Agents, Biomedical Research, Duration of Therapy, Female, Guidelines as Topic, HIV Infections, Humans, Male, Middle Aged, Remission Induction, Research Design, Risk Factors, Sexual Partners, HIV, research ethics, analytic treatment interruption, HIV cure-related studies, immunotherapy, pre-exposure prophylaxis, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Ethical guidelines and recommendations for human subjects research typically focus on protecting the individuals who directly participate in that research. However, additional people, including sex partners of research participants, can also face harms and burdens from medical studies. In human immunodeficiency virus (HIV) cure-related research, a persistent ethical and practical challenge surrounds the use of analytical antiretroviral treatment interruptions. The challenge is usually discussed in relation to risks to study participants, but serious dangers accrue to nonparticipants, including sex partners of study participants. This multidisciplinary supplement relays the risks for nonparticipating sex partners in HIV cure-related studies and addresses the ethical dilemmas raised by these studies, with recommendations for researchers, advocates, sponsors, and oversight bodies.

Published
2019

12. Ethical issues in HIV remission trials

Author

Eyal, Nir, Holtzman, Lisa G, and Deeks, Steven G

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Minority Health, Women's Health, Clinical Research, Infectious Diseases, Sexually Transmitted Infections, Behavioral and Social Science, Clinical Trials and Supportive Activities, HIV/AIDS, 8.3 Policy, ethics, and research governance, Health and social care services research, Infection, Clinical Trials as Topic, Ethics, Medical, Guidelines as Topic, HIV, HIV Infections, Humans, Remission Induction, analytic treatment interruption, HIV cure-related studies, human subjects research, immunotherapy, research ethics, Public Health and Health Services, Virology, Clinical sciences, Medical microbiology, Epidemiology
Abstract

Purpose of reviewSeveral promising experimental pathways exist for long-term control of HIV in the absence of antiretroviral therapy (HIV 'remission') and are now being tested in early clinical studies. These studies can be invasive and pose a host of distinctive risks to participants, as well as to nonparticipants, especially to participants' fetuses, and sexual partners.Recent findingsEthical analyses of these studies have mainly focused on the risks to study participants. They recommend, and some investigators implement, procedures to mitigate risks for participants or to offset them with direct, indirect, and nonmedical benefits. They also suggest ways to keep participants' consent highly voluntary and informed. Rarely do ethicists propose keeping the social value of studies high. Of these recommended responses, only the latter, rarer proposals help address the risk to nonparticipants, as would some novel ways to address that risk.SummaryHIV remission studies pose a number of ethical dilemmas. Many current investigative approaches put the participant at significant risk, but well established guidelines exist for mitigating this risk. Ethical issues that are not being fully addressed include risk to nonparticipants and the need to consider the societal value of studies, for example, their prospective impact on the global HIV burden. VIDEO ABSTRACT.

Published
2018

19. Willingness to trade-off years of life for an HIV cure – an experimental exploration of affective forecasting.

Author

Fridman, Ilona, Eyal, Nir, Scherr, Karen A., Currier, Judith S., Freedberg, Kenneth A., Halpern, Scott D., Kuritzkes, Daniel R., Magalhaes, Monica, Pollak, Kathryn I., and Ubel, Peter A.

Subjects
*HEALTH attitudes, *RESEARCH funding, *LIFE expectancy, *STATISTICAL sampling, *QUESTIONNAIRES, *HIV infections, *DECISION making in clinical medicine, *RANDOMIZED controlled trials, *MULTIVARIATE analysis, *DESCRIPTIVE statistics, *QUALITY of life, *ANALYSIS of variance, *ANTI-HIV agents, *FORECASTING
Abstract

Background: In the US, 1.2 million people live with HIV (PWH). Despite having near-normal life expectancies due to antiretroviral therapy (ART), many PWH seek an HIV cure, even if it means risking their lives. This willingness to take risks for a cure raises questions about "affective forecasting biases," where people tend to overestimate the positive impact of future events on their well-being. We conducted a study to test two interventions to mitigate affective forecasting in the decisions of PWH about taking HIV cure medication. Methods: We recruited PWH to complete a 30-minute survey about their current quality of life (QoL) and the QoL they anticipate after being cured of HIV, and assigned them to either no additional intervention, to one of two interventions intended to reduce affective forecasting bias, or to both interventions: (1) a defocusing intervention designed to broaden the number of life domains people consider when imagining life changes associated with new circumstances (e.g. HIV cure); and (2) an adaptation intervention to help them gauge fading of strong emotions over time. The study design included a 2 × 2 design: defocusing (yes/no) x adaptation (yes/no) intervention. We assessed PWH's willingness to take hypothetical HIV sterilizing cure medication using the Time Trade-Off (TTO) and their quality of life predictions with WHOQOL-HIV. Results: 296 PWH participated. Counter to what we had hypothesized, neither intervention significantly reduced PWH's willingness to trade time for a cure. Instead, the defocusing intervention increased their willingness to trade time (IRR 1.77, p = 0.03). Exploratory analysis revealed that PWH with lower current quality of life who received the defocusing intervention were more willing to trade time for a cure. Conclusion: These negative findings suggest that either these biases are difficult to overcome in the settings of HIV curative medication or other factors beyond affective forecasting biases influence willingness to participate in HIV curative studies, such as respondents' current quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. International AIDS Society global scientific strategy: towards an HIV cure 2016

Author

Deeks, Steven G, Lewin, Sharon R, Ross, Anna Laura, Ananworanich, Jintanat, Benkirane, Monsef, Cannon, Paula, Chomont, Nicolas, Douek, Daniel, Lifson, Jeffrey D, Lo, Ying-Ru, Kuritzkes, Daniel, Margolis, David, Mellors, John, Persaud, Deborah, Tucker, Joseph D, Barre-Sinoussi, Françoise, Alter, Galit, Auerbach, Judith, Autran, Brigitte, Barouch, Dan H, Behrens, Georg, Cavazzana, Marina, Chen, Zhiwei, Cohen, Éric A, Corbelli, Giulio Maria, Eholié, Serge, Eyal, Nir, Fidler, Sarah, Garcia, Laurindo, Grossman, Cynthia, Henderson, Gail, Henrich, Timothy J, Jefferys, Richard, Kiem, Hans-Peter, McCune, Joseph, Moodley, Keymanthri, Newman, Peter A, Nijhuis, Monique, Nsubuga, Moses Supercharger, Ott, Melanie, Palmer, Sarah, Richman, Douglas, Saez-Cirion, Asier, Sharp, Matthew, Siliciano, Janet, Silvestri, Guido, Singh, Jerome, Spire, Bruno, Taylor, Jeffrey, Tolstrup, Martin, Valente, Susana, van Lunzen, Jan, Walensky, Rochelle, Wilson, Ira, and Zack, Jerome

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Good Health and Well Being, Acquired Immunodeficiency Syndrome, Goals, HIV Infections, Humans, International Cooperation, Organizational Objectives, Research, Societies, Medical, International AIDS Society Towards a Cure Working Group, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a global population of more than 35 million people living with HIV, there is intense interest in developing a cure for HIV infection. The International AIDS Society convened a group of international experts to develop a scientific strategy for research towards an HIV cure. This Perspective summarizes the group's strategy.

Published
2016

27. Joint statement in support of hepatitis C human challenge studies

Author

Alter, Harvey J, primary, Barnes, Eleanor, additional, Biondi, Mia J, additional, Cox, Andrea L, additional, Eberts, Jake D, additional, Feld, Jordan J, additional, Liang, T Jake, additional, Morrison, Josh, additional, Rice, Charles M, additional, Shoukry, Naglaa H, additional, Thomas, David L, additional, Van Gennip, Jennifer, additional, Weijer, Charles, additional, Aghemo, Alessio, additional, Akiyama, Matthew, additional, Ali, Mohammad, additional, Alter, Harvey, additional, Bader, Ralf, additional, Bailey, Justin R., additional, Balaban, Yasemin, additional, Banerjee, Sayantan, additional, Bartenschlager, Ralf, additional, Baumert, Thomas F., additional, Berenguer, Marina, additional, Bhadoria, Ajeet S., additional, Biondi, Mia, additional, Bonanni, Paolo, additional, Bonella, Alcino E., additional, Bruggmann, Philip, additional, Bruneau, Julie, additional, Bull, Rowena A., additional, Butsashvili, Maia, additional, Cahn, Pedro, additional, Caplan, Arthur L., additional, Chappell, Richard Y., additional, Chisari, Francis, additional, Chung, Ray, additional, Cooke, Graham, additional, Cox, Andrea L., additional, Dalgard, Olav, additional, Dao, Doan Y., additional, Darzi, Ara, additional, Dieterich, Douglas, additional, Dillon, John F., additional, Dore, Gregory J., additional, Doyle, Joseph S., additional, Drummer, Heidi E., additional, Durbin, Anna P., additional, Dusheiko, Geoffrey, additional, Eberts, Jake D., additional, Eyal, Nir, additional, Feld, Jordan, additional, Ferguson, Kyle, additional, Flisiak, Robert, additional, Forns, Xavier, additional, Foster, Graham R., additional, Foung, Steven, additional, Gal-Tanamy, Meital, additional, Gane, Ed, additional, Gehring, Adam J., additional, George, Jacob, additional, Ghany, Marc G., additional, Gilbert, Daniel T., additional, Glaze, Kimberly, additional, Goodman, Kenneth W., additional, Grebely, Jason, additional, Hamid, Saeed, additional, Haybron, Daniel M., additional, Holton, Richard, additional, Ignarro, Louis J., additional, Jackson, Tamika, additional, Jamieson, Dale, additional, Jollimore, Jody, additional, Karaba, Andrew, additional, Klein, Marina, additional, Lauer, Georg, additional, Law, Mansun, additional, Lemon, Stanley M., additional, Liang, T. Jake, additional, Liu, Lin, additional, Lohmann, Volker, additional, Mak, Lung-Yi, additional, Marinho, Rui T., additional, Marsh, Abigail A., additional, Miller, Lesley, additional, Morrison, Joshua, additional, Negro, Francesco, additional, Nguyen, Bao-Vuong, additional, Page, Kimberly, additional, Paterson, Kerry, additional, Pedrana, Alisa, additional, Pietschmann, Thomas, additional, Pinker, Steven, additional, Plotkin, Stanley, additional, Ray, Stuart C., additional, Reau, Nancy, additional, Remak, William M., additional, Rice, Charles M., additional, Ridruejo, Ezequiel, additional, Roberts, Richard J., additional, Roth, Alvin, additional, Rouphael, Nadine, additional, Sanders, Rogier, additional, Sandvold, Russell, additional, Schafer, Arthur, additional, Schinkel, Janke, additional, Seto, Wai-Kay, additional, Shoukry, Naglaa, additional, Singer, Peter, additional, Solomon, Sunil, additional, Somerville, Chris, additional, Sonderup, Mark W., additional, Sulkowski, Mark, additional, Talaat, Kawsar, additional, Temkin, Larry, additional, Terrault, Norah, additional, Thio, Chloe, additional, Thomas, David L., additional, Thompson, Alexander J., additional, Tzarum, Netanel, additional, van der Valk, Marc, additional, Waked, Imam, additional, Walen, Alec, additional, Walker, Christopher M., additional, Wedemeyer, Heiner, additional, Wikler, Dan, additional, Wilkinson, Dominic, additional, Youngs, Heather, additional, Yuen, Man-fung, additional, Zack, Barry, additional, and Zinger, Ekaterina, additional

Published
2023
Full Text
View/download PDF

33. Introduction

Author

Eyal, Nir, additional, Hurst, Samia A., additional, Murray, Christopher J. L., additional, Schroeder, S. Andrew, additional, and Wikler, Daniel, additional

Published
2020
Full Text
View/download PDF

42. Three Case Studies in Making Fair Choices on the Path to Universal Health Coverage

Author

VOORHOEVE, ALEX, EDEJER, TESSA T.T., KAPIRIRI, LYDIA, NORHEIM, OLE F., SNOWDEN, JAMES, BASENYA, OLIVIER, BAYARSAIKHAN, DORJSUREN, CHENTAF, IKRAM, EYAL, NIR, FOLSOM, AMANDA, HUSSEIN, ROZITA HALINA TUN, MORALES, CRISTIAN, OSTMANN, FLORIAN, OTTERSEN, TRYGVE, PRAKONGSAI, PHUSIT, SAENZ, CARLA, SALEH, KARIMA, SOMMANUSTWEECHAI, ANGKANA, WIKLER, DANIEL, and ZAKARIAH, AFISAH

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results